Vertex Pharmaceuticals (VRTX) Deferred Taxes (2011 - 2026)

Vertex Pharmaceuticals' Deferred Taxes history runs 16 years deep, the most recent figure standing at -$65.3 million for Q1 2026.

• On a quarterly basis, Deferred Taxes rose 65.92% year-over-year to -$65.3 million in Q1 2026; TTM through Mar 2026 was -$384.5 million, a 0.63% decrease from a year earlier, with the FY2025 full-year figure at -$510.8 million, down 46.44% from the prior year.
• Deferred Taxes slipped to -$65.3 million in Q1 2026 per VRTX's latest filing, from $30.5 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $148.1 million in Q4 2022 and bottomed at -$235.9 million in Q3 2025.
• The 5-year median for Deferred Taxes is -$118.8 million (2024), against an average of -$102.2 million.
• Across the five-year window, Deferred Taxes soared 453.46% in 2022 and sank 821.95% in 2023, its largest moves.
• Year by year, Deferred Taxes stood at $148.1 million in 2022, then slumped by 188.45% to -$131.0 million in 2023, then jumped by 139.39% to $51.6 million in 2024, then plunged by 40.89% to $30.5 million in 2025, then plunged by 314.1% to -$65.3 million in 2026.
• Per Business Quant, the three latest VRTX Deferred Taxes figures stand at -$65.3 million (Q1 2026), $30.5 million (Q4 2025), and -$235.9 million (Q3 2025).